This HTML5 document contains 179 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n10http://dx.doi.org/10.1038/
n12http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
n13https://scigraph.springernature.com/pub.10.1038/
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q36611825
rdf:type
wikibase:Item
schema:description
2006年论文 wissenschaftlicher Artikel artikull shkencor научни чланак artigo científico vetenskaplig artikel 2006年論文 научни чланак научная статья scienca artikolo teaduslik artikkel artikel ilmiah 2006年論文 2006年论文 naučni članak ৩ অক্টোবর ২০০৬-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ videnskabelig artikel 2006年論文 articolo scientifico 2006 թվականի հոկտեմբերի 3-ին հրատարակված գիտական հոդված article scientifique vedecký článok article scientific 2006 nî lūn-bûn articol științific 2006年论文 artikulong pang-agham scientific article published on 3 October 2006 vitskapeleg artikkel 2006年论文 мақолаи илмӣ vědecký článek artículo científico publicado en 2006 מאמר מדעי wetenschappelijk artikel επιστημονικό άρθρο artigo científico artykuł naukowy 2006年论文 scientific article published on 3 October 2006 vitenskapelig artikkel scientific article published on 3 October 2006 bilimsel makale bài báo khoa học 2006年論文 tieteellinen artikkeli مقالة علمية نشرت في 3 أكتوبر 2006 2006年論文 artigo científico научна статия სამეცნიერო სტატია 2006年の論文 2006年论文 tudományos cikk บทความทางวิทยาศาสตร์ 2006년 논문 artículu científicu espublizáu en 2006 наукова стаття, опублікована в жовтні 2006 article científic
p:P577
wds:Q36611825-44EF7F70-2453-43F7-AB6F-A81B229FC35D
wdt:P577
2006-10-03T00:00:00Z
p:P407
wds:Q36611825-EA1331E3-61DA-453F-B72A-318353E90BBD
wdt:P407
wd:Q1860
p:P2888
wds:Q36611825-818706F6-8FDE-4EF7-9DFE-CFB2376069C2
wdt:P2888
n13:sj.bjc.6603376
p:P2860
wds:Q36611825-D96E825E-51F4-42A2-AF44-8AD0C1EB1275 wds:Q36611825-DEF23EC0-4867-4F71-9238-612680A7AEE3 wds:Q36611825-F65098E7-2827-416E-8D4F-C999EF521C70 wds:Q36611825-FB5F215E-9294-49CF-9001-A874B0F7A8AB wds:Q36611825-FD32BF7E-BB6A-467B-95F3-04FBF57F7118 wds:Q36611825-0D0C678D-C497-4BA9-8EA7-99097FFB92AF wds:Q36611825-0E205D29-3F24-4FF7-A74D-984FB9D1172E wds:Q36611825-1FF4C56E-2A4D-4BA4-B2CD-B849A9E08D37 wds:Q36611825-244D3E01-78A3-4371-80E9-A7BB8CC8BDBB wds:Q36611825-246E3BCE-2CAC-4691-8949-BC45450AD2C8 wds:Q36611825-2A2A4377-43EA-47B0-8B56-957CAAB424CC wds:Q36611825-304925FC-2853-4FED-B650-FAD827A3DD2E wds:Q36611825-32BA10A5-2BB1-4C2B-ABA1-ABB792734433 wds:Q36611825-36BCD57F-F1DB-4C35-8597-1B340F358723 wds:Q36611825-483D4871-4B94-406E-A200-2BD0170215D3 wds:Q36611825-4E6A8AB5-3822-4F8D-8788-E60701D4BFB6 wds:Q36611825-57A1ECD9-0BEC-4395-A493-CAB789878936 wds:Q36611825-7247F56C-F1D9-47AF-8A79-5A6A0AD605A1 wds:Q36611825-728182A3-0D95-4631-8D5F-B35FB93E1C34 wds:Q36611825-7A07D18A-E392-4110-9A97-141E7723049D wds:Q36611825-803DC1DF-FC52-4F92-979F-16A064614170 wds:Q36611825-85117E24-F4A1-412F-9F7E-C56E164194A5 wds:Q36611825-8B71F6C7-07FE-4358-9974-11F992D28D41 wds:Q36611825-A8D79545-161F-436D-B09F-99CD6F30E7FB wds:Q36611825-ABD760C3-F531-4A80-B76F-FA4A51AA55E5 wds:Q36611825-AED6220D-55F6-4362-9F5B-E333DB640A04 wds:Q36611825-B15E3DE6-0630-42FE-A319-E259D8F548A2 wds:Q36611825-BFD93B3C-E6EE-4FC8-AEDA-A0199142C3A5
wdt:P2860
wd:Q35650039 wd:Q46551694 wd:Q36621800 wd:Q44927364 wd:Q33334642 wd:Q35213979 wd:Q44781447 wd:Q45009128 wd:Q40522471 wd:Q71468768 wd:Q73208076 wd:Q36115025 wd:Q34310201 wd:Q38790464 wd:Q48331144 wd:Q44108566 wd:Q33347264 wd:Q33358579 wd:Q44480732 wd:Q25938997 wd:Q28344315 wd:Q30647642 wd:Q24631957 wd:Q33915548 wd:Q36735911 wd:Q33503863 wd:Q27824832 wd:Q27860910
p:P2093
wds:Q36611825-C738BF8A-9953-4A39-B1C9-70938AFB3561 wds:Q36611825-CCCB5116-DC0C-463D-A8D9-6A700DB7C05B wds:Q36611825-FEE37D1F-3D74-48EE-AEA0-0CBC567C03BA wds:Q36611825-FB577FD4-13D8-4A31-947A-99B734A9359E wds:Q36611825-BFEB22A1-2466-46B7-8F31-4A015BCA8A46 wds:Q36611825-C2EBA8F3-4C91-43C7-A9C5-6FC8D9F99C27 wds:Q36611825-45715400-BDB4-4E68-AD42-D911A01DEA8F wds:Q36611825-326D468E-AD95-45A7-AE39-0679C89BFE6C wds:Q36611825-093B18AE-1653-4ADF-9E61-0A2E648EF82C
wdt:P2093
L Crinò A Tosoni M Biscuola V Gioia R Bertorelle G Cavallo GICNO M Ermani V Blatt
rdfs:label
Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO).
skos:prefLabel
Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO).
schema:name
Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO).
p:P50
wds:Q36611825-97BA2A3B-E7A5-498F-83AA-59452B7C507E wds:Q36611825-68FBC335-91CA-4482-BED8-5F143617BFEC
wdt:P50
wd:Q57048436 wd:Q51349290
p:P1476
wds:Q36611825-D8D1323E-B6AB-444F-B305-659109A86630
wdt:P1476
Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO)
p:P304
wds:Q36611825-A474AD97-DD60-4CEE-AD81-D68563FFC04C
wdt:P304
1155-1160
p:P31
wds:Q36611825-0F73200C-584F-431E-A894-598A08F08B97
wdt:P31
wd:Q13442814
p:P921
wds:Q36611825-E6AD7CD7-9E98-4707-B3B9-B5C44E4DFF62 wds:Q36611825-B0E90194-0883-4676-BB71-B7F8BD561C14
wdt:P921
wd:Q425088 wd:Q282142
p:P698
wds:Q36611825-7364722F-6B47-42B4-B990-2D842E91BD47
wdtn:P698
n12:17024124
wdt:P698
17024124
p:P1433
wds:Q36611825-3B639CE8-9691-4FCE-B41C-E0DD1EA48471
wdt:P1433
wd:Q326309
p:P433
wds:Q36611825-4F1CECE1-E02C-4EBD-BEF0-0D13BA3493E2
p:P478
wds:Q36611825-A6F36F2F-FECB-4EE7-A651-C19FD61CBA59
wdt:P433
9
wdt:P478
95
p:P356
wds:Q36611825-2697EB3E-C3D7-4B8C-B8E3-73F1CCB7305A
wdtn:P356
n10:SJ.BJC.6603376
wdt:P356
10.1038/SJ.BJC.6603376
p:P5875
wds:Q36611825-D2E0DC4D-FF58-4A18-911B-F4396773210E
wdt:P5875
6771195
p:P932
wds:Q36611825-9EADE1EE-3974-4812-A0B6-AE7E61B53F2A
wdt:P932
2360560